<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393807</url>
  </required_header>
  <id_info>
    <org_study_id>B7411002</org_study_id>
    <secondary_id>SARM FOOD EFFECT &amp; BE</secondary_id>
    <secondary_id>SARM FOOD EFFECT &amp;BE</secondary_id>
    <nct_id>NCT02393807</nct_id>
  </id_info>
  <brief_title>The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation</brief_title>
  <official_title>A Phase 1 Single-dose Open Label 3-way Crossover Study To Evaluate The Bioavailability Of A Spray Dried Dispersion Solid Dose Formulation Of Pf-06260414 Relative To A Suspension Formulation Under Fasted Conditions And The Effect Of Food On The Bioavailability Of The Pf-06260414 Spray Dried Dispersion Solid Formulation In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will investigate the relative bioavailability of a spray dried dispersion
      solid dose formulation of PF 06260414 administered as a single oral dose of 30 mg of PF
      06260414 relative to a single oral dose of 30 mg of PF 06260414 administered as a
      nanosuspension under fasted or fed conditions in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single dose pharmacokinetics under fasted condition: Cmax of PF- 06260414 formulations</measure>
    <time_frame>Hour 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose pharmacokinetics under fasted condition: AUClast of PF- 06260414 formulations</measure>
    <time_frame>Hour 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose pharmacokinetics under fed condition: Cmax of PF- 06260414 formulations</measure>
    <time_frame>Hour 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose pharmacokinetics under fed condition: AUClast of PF- 06260414 formulations</measure>
    <time_frame>Hour 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of PF-06260414</measure>
    <time_frame>Hour 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tÂ½ of PF-06260414</measure>
    <time_frame>Hour 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of PF-06260414</measure>
    <time_frame>Hour 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Open label single dose crossover study of PF-06260414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This will be a Phase 1, open label, randomized, single dose, 3 period, 3 way crossover study to evaluate the relative bioavailability of solid dose formulation of PF 06260414 under fasted conditions compared to the nanosuspension under fasted conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF 06260414 solid dose formulation</intervention_name>
    <description>Single dose of 30 mg PF-06260414 given under fed/fasted conditions</description>
    <arm_group_label>Open label single dose crossover study of PF-06260414</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06260414 nanosuspension</intervention_name>
    <description>Single dose of 30 mg PF-06260414 given under fasted conditions</description>
    <arm_group_label>Open label single dose crossover study of PF-06260414</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects of non childbearing potential between the ages of
             18 and 55 years, inclusive.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease

          -  Any condition possibly affecting drug absorption (eg, gastrectomy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

